Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients

贝伐单抗 医学 肿瘤科 结直肠癌 药代动力学 内科学 癌胚抗原 混淆 危险系数 养生 比例危险模型 癌症 化疗 置信区间
作者
Sarah Lobet,Morgane Caulet,Gilles Paintaud,Nicolas Azzopardi,Céline Desvignes,Romain Chautard,Christophe Borg,Olivier Capitain,Aurélie Ferru,Olivier Bouché,Thierry Lecomte,David Ternant
出处
期刊:British Journal of Clinical Pharmacology [Wiley]
卷期号:90 (4): 976-986 被引量:1
标识
DOI:10.1111/bcp.15983
摘要

Aims The exposure‐response relationship of bevacizumab may be confounded by various factors, including baseline characteristics, time‐dependent target engagement and recursive relationships between exposure and response, requiring effective mitigation. This study aimed to investigate the exposure‐response relationships of bevacizumab in metastatic colorectal cancer (mCRC) patients while mitigating potential biases. Methods Bevacizumab pharmacokinetics was described using target‐mediated drug disposition modelling. Relationships between target kinetics, progression‐free (PFS) and overall (OS) survivals were assessed using joint pharmacokinetic and parametric hazard function models. Both prognostic‐driven and response‐driven potential biases were mitigated. These models evaluated the impact of increased antigen target levels, clearance and intensified dosing regimen on survival. Results Estimated target‐mediated pharmacokinetic parameters in 130 assessed patients were baseline target levels ( R 0 = 8.4 nM), steady‐state dissociation constant ( K SS = 10 nM) and antibody‐target complexes elimination constant ( k int = 0.52 day −1 ). The distribution of R 0 was significantly associated with increased baseline concentrations of carcinoembryonic antigen, circulating vascular endothelial growth factor and the presence of extrahepatic metastases. Unbound target levels ( R ) significantly influenced both progression and death hazard functions. Increasing baseline target levels and/or clearance values led to decreased bevacizumab unbound concentrations, increased R levels and shortened PFS and OS, while increasing bevacizumab dose led to decreased R and longer survival. Conclusion This study is the first to demonstrate the relationship between bevacizumab concentrations, target involvement and clinical efficacy by effectively mitigating potential sources of bias. Most of the target amount may be tumoural in mCRC. Future studies should provide a more in‐depth description of this relationship.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
木马上市完成签到,获得积分10
1秒前
zz完成签到,获得积分10
2秒前
Yangyang完成签到,获得积分10
3秒前
纯真大碗完成签到,获得积分10
4秒前
gs完成签到,获得积分10
4秒前
碧蓝幻香发布了新的文献求助10
4秒前
5秒前
赘婿应助燕子采纳,获得10
5秒前
6秒前
开始游戏55完成签到,获得积分10
6秒前
jin_strive完成签到,获得积分10
6秒前
7秒前
暖暖完成签到,获得积分10
8秒前
8秒前
不解歌发布了新的文献求助30
8秒前
顺心香菇完成签到,获得积分10
8秒前
ps2666完成签到 ,获得积分10
8秒前
10秒前
shadow完成签到,获得积分10
11秒前
蒋若风完成签到,获得积分10
12秒前
LULU发布了新的文献求助10
12秒前
包子牛奶完成签到,获得积分10
12秒前
14秒前
zqx完成签到,获得积分10
14秒前
14秒前
14秒前
酷波er应助小象采纳,获得10
14秒前
宝宝哎呀哦完成签到,获得积分10
15秒前
鸢尾不是板蓝根完成签到,获得积分10
16秒前
清酒少年游完成签到,获得积分10
16秒前
KYDD完成签到,获得积分10
19秒前
高健伟发布了新的文献求助10
19秒前
杨老师完成签到 ,获得积分10
19秒前
葛怀锐完成签到 ,获得积分10
19秒前
Wu完成签到,获得积分10
20秒前
喝开水完成签到 ,获得积分10
20秒前
鹏gg完成签到,获得积分10
20秒前
冷傲迎梦发布了新的文献求助10
20秒前
天天发布了新的文献求助10
20秒前
懦弱的硬币完成签到,获得积分10
20秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Continuum Thermodynamics and Material Modelling 2000
Encyclopedia of Geology (2nd Edition) 2000
105th Edition CRC Handbook of Chemistry and Physics 1600
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 1500
Izeltabart tapatansine - AdisInsight 800
Maneuvering of a Damaged Navy Combatant 650
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3773724
求助须知:如何正确求助?哪些是违规求助? 3319325
关于积分的说明 10194278
捐赠科研通 3033980
什么是DOI,文献DOI怎么找? 1664844
邀请新用户注册赠送积分活动 796364
科研通“疑难数据库(出版商)”最低求助积分说明 757433